Top Suppliers:I want be here



6501-72-0

6501-72-0 structure
6501-72-0 structure
  • Name: VGX-1027(Git-27)
  • Chemical Name: 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
  • CAS Number: 6501-72-0
  • Molecular Formula: C11H11NO3
  • Molecular Weight: 205.210
  • Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
  • Create Date: 2016-02-05 02:49:00
  • Modify Date: 2024-01-03 16:45:00
  • VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.IC50 value: Target: immunomodulatorAdministration of VGX-1027 to NOD mice with spontaneous or accelerated forms of diabetes induced either by injection of cyclophosphamide or by transfer of spleen cells from acutely diabetic syngeneic donors markedly reduced the cumulative incidence of diabetes and insulitis. In addition, VGX-1027 given either i.p. or p.o. to CBA/H mice made diabetic with multiple low doses of streptozotocin successfully counteracted the development of destructive insulitis and hyperglycemia [1]. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-gamma and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA [2]. VGX-1027 inhibited both proliferation of enterobacterial antigen-reactive CD4+CD25- T cells in vitro and the development of clinical and histological signs of colitis in vivo [3].

Name 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
Synonyms GIT 27
3-phenyl-4,5-dihydro-5-isoxazoleacetic acid
4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID
(3-Phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
5-Isoxazoleacetic acid, 4,5-dihydro-3-phenyl-
VGX-1027
Description VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.IC50 value: Target: immunomodulatorAdministration of VGX-1027 to NOD mice with spontaneous or accelerated forms of diabetes induced either by injection of cyclophosphamide or by transfer of spleen cells from acutely diabetic syngeneic donors markedly reduced the cumulative incidence of diabetes and insulitis. In addition, VGX-1027 given either i.p. or p.o. to CBA/H mice made diabetic with multiple low doses of streptozotocin successfully counteracted the development of destructive insulitis and hyperglycemia [1]. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-gamma and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA [2]. VGX-1027 inhibited both proliferation of enterobacterial antigen-reactive CD4+CD25- T cells in vitro and the development of clinical and histological signs of colitis in vivo [3].
Related Catalog
References

[1]. Stosic-Grujicic S, et al. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multipl

[2]. Stojanovic I, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin Immuno

[3]. Mangano K, et al. In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur J Pharmacol. 2008 May 31;586(1-3):313-21.

Density 1.3±0.1 g/cm3
Boiling Point 381.4±34.0 °C at 760 mmHg
Melting Point 159 °C
Molecular Formula C11H11NO3
Molecular Weight 205.210
Flash Point 184.5±25.7 °C
Exact Mass 205.073898
PSA 58.89000
LogP 1.16
Vapour Pressure 0.0±0.9 mmHg at 25°C
Index of Refraction 1.601

~%

6501-72-0 structure

6501-72-0

Literature: GANIAL IMMUNOTHERAPEUTICS INC. Patent: WO2006/97273 A1, 2006 ; Location in patent: Page/Page column 13 ;

~%

6501-72-0 structure

6501-72-0

Literature: Eichinger, Karl; Wokurek, Michael; Zauner, Bernd; Rostami, Mohammad Reza Synthetic Communications, 1997 , vol. 27, # 16 p. 2733 - 2742

~%

6501-72-0 structure

6501-72-0

Literature: Stosic-Grujicic, Stanislava; Cvetkovic, Ivana; Mangano, Katia; Fresta, Massimo; Maksimovic-Ivanic, Danijela; Harhaji, Ljubica; Popadic, Dusan; Momcilovic, Miljana; Miljkovic, Djordje; Kim, Joseph; Al Abed, Yousef; Nicoletti, Ferdinando Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 3 p. 1038 - 1049
Precursor  3

DownStream  0